Adjuvant Effect of Rosuvastatin Combined with Losartan Potassium on Peritoneal Dialysis Patients
In recent years, with the development of blood purification technology, peritoneal dialysis has become the main alternative therapy for end-stage renal disease patients. The residual renal function is closely related to the survival rate and quality of life in patients with peritoneal dialysis. The function of residual renal is used not only to remove the functions of small molecules and large molecules in the body, but also to regulate the acid-base balance of water, electrolytes and some endocrine functions.
Angiotensin II receptor antagonist (ARB), as an effective RAS blocker, is mainly related to the paracrine of the angiotensin II (angiotensin II, Ang II). The results of some animal experiments showed that in a long-term peritoneal dialysis model, the RAS blocker played an active role in resisting the proliferation and hardening of the peritoneum and protecting the peritoneum. And it also has protective effect on residual renal function in patients with end-stage renal disease. The main mechanism is that ARB can prevent peritoneal fibrosis by inhibiting the expression of TGF-1. Losartan can improve peritoneal micro inflammation, inhibit the occurrence of peritonitis and slow down the decrease of residual renal function, and increase the rate of peritoneal UF to decrease and solute transport. It is confirmed again that these drugs have protective effects on peritoneal function.
However, the peritoneum of peritoneal dialysis patients is always in a high glucose environment. It is similar to the microenvironment of diabetic patients. Therefore statins may inhibit peritonitis and reduce peritoneal fibrosis. Therefore, the treatment of rosuvastatin combined with losartan potassium can effectively protect the residual renal function, improve the state of micro inflammation, inhibit the peritoneal fibrosis and improve the quality of life of the patients with peritoneal dialysis.